(Q35023441)

English

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 August 2017

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas (English)

1 reference

Europe PubMed Central

5 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

19

object named as

Kelly Hunt

1 reference

Europe PubMed Central

5 August 2017

11

object named as

Laura J Esserman

1 reference

Europe PubMed Central

5 August 2017

2

object named as

Vera J Suman

1 reference

Europe PubMed Central

5 August 2017

Gildy V Babiera

14

object named as

Gildy V Babiera

1 reference

Europe PubMed Central

5 August 2017

author name string

Matthew J Ellis

1

1 reference

Europe PubMed Central

5 August 2017

Jeremy Hoog

3

1 reference

Europe PubMed Central

5 August 2017

Li Lin

4

1 reference

Europe PubMed Central

5 August 2017

Jacqueline Snider

5

1 reference

Europe PubMed Central

5 August 2017

Aleix Prat

6

1 reference

Europe PubMed Central

5 August 2017

Joel S Parker

7

1 reference

Europe PubMed Central

5 August 2017

Jingqin Luo

8

1 reference

Europe PubMed Central

5 August 2017

Katherine DeSchryver

9

1 reference

Europe PubMed Central

5 August 2017

D Craig Allred

10

1 reference

Europe PubMed Central

5 August 2017

Gary W Unzeitig

12

1 reference

Europe PubMed Central

5 August 2017

Julie Margenthaler

13

1 reference

Europe PubMed Central

5 August 2017

P Kelly Marcom

15

1 reference

Europe PubMed Central

5 August 2017

Joseph M Guenther

16

1 reference

Europe PubMed Central

5 August 2017

Mark A Watson

17

1 reference

Europe PubMed Central

5 August 2017

Marilyn Leitch

18

1 reference

Europe PubMed Central

5 August 2017

John A Olson

20

1 reference

Europe PubMed Central

5 August 2017

language of work or name

0 references

publication date

9 May 2011

1 reference

Europe PubMed Central

5 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

5 August 2017

29

1 reference

Europe PubMed Central

5 August 2017

2342-2349

1 reference

Europe PubMed Central

5 August 2017

17

1 reference

Europe PubMed Central

5 August 2017

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

8 July 2018

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

8 July 2018

Breast cancer molecular profiling with single sample predictors: a retrospective analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

8 July 2018

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

8 July 2018

Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

8 July 2018

Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

8 July 2018

Supervised risk predictor of breast cancer based on intrinsic subtypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

8 July 2018

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

8 July 2018

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

8 July 2018

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

8 July 2018

Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

8 July 2018

Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

25 October 2018

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

25 October 2018

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

25 October 2018

Neoadjuvant endocrine therapy for breast cancer: more questions than answers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

25 October 2018

Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

25 October 2018

Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

25 October 2018

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

25 October 2018

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

25 October 2018

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

25 October 2018

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107749

25 October 2018

Preoperative systemic chemotherapy and pathologic assessment of response

1 reference

https://pubmed.ncbi.nlm.nih.gov/21555689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical implementation of the intrinsic subtypes of breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21555689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://pubmed.ncbi.nlm.nih.gov/21555689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21555689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2010.31.6950

1 reference

Europe PubMed Central

5 August 2017

release_xnezc4mk75hnjbj6ib7iwejk64

1 reference

https://api.fatcat.wiki/v0/release/xnezc4mk75hnjbj6ib7iwejk64

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

5 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35023441&oldid=2121315377"